7.45
-0.32 (-4.12%)
| Previous Close | 7.77 |
| Open | 7.82 |
| Volume | 83,377 |
| Avg. Volume (3M) | 746,535 |
| Market Cap | 221,782,512 |
| Price / Earnings (TTM) | 2.37 |
| Price / Sales | 2.64 |
| Price / Book | 2.68 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -7.57 |
| Total Debt/Equity (MRQ) | 333.06% |
| Current Ratio (MRQ) | 4.71 |
| Operating Cash Flow (TTM) | -65.65 M |
| Levered Free Cash Flow (TTM) | -48.59 M |
| Return on Assets (TTM) | -33.79% |
| Return on Equity (TTM) | -267.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Q32 Bio Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.00 |
Select this tab to load the latest available analysis.
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.57% |
| % Held by Institutions | 73.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Boxer Capital Management, Llc | 30 Jun 2026 | 3,149,310 |
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2026 | 2,717,106 |
| Opaleye Management Inc. | 30 Jun 2026 | 931,000 |
| Logos Global Management Lp | 30 Jun 2026 | 800,000 |
| Summittx Capital, L.P. | 30 Jun 2026 | 733,774 |
| Woodline Partners Lp | 30 Jun 2026 | 286,212 |
| Sanofi | 30 Jun 2026 | 244,083 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KALOWSKI LEE | - | 8.11 | -1,301 | -10,551 |
| MORRISON JODIE POPE | - | 8.11 | -3,221 | -26,122 |
| VIOLETTE SHELIA M. | - | 8.11 | -917 | -7,437 |
| Aggregate Net Quantity | -5,439 | |||
| Aggregate Net Value ($) | -44,110 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KALOWSKI LEE | Officer | 06 Oct 2026 | Sell (-) | 1,301 | 8.11 | 10,551 |
| VIOLETTE SHELIA M. | Officer | 06 Oct 2026 | Sell (-) | 917 | 8.11 | 7,437 |
| MORRISON JODIE POPE | Officer | 06 Oct 2026 | Sell (-) | 3,221 | 8.11 | 26,122 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |